Study Links Vaping to Irregular Heartbeats in Mice

Nov.03.2022
Study Links Vaping to Irregular Heartbeats in Mice
A study on e-cigarette liquids causing heart rhythm disruption in mice is criticized for its lack of relevance to humans.

A newspaper has reported on a study claiming that electronic cigarette liquid can disrupt heart rhythms, but has failed to highlight that the study was conducted on mice and involved toxic doses. An expert on tobacco reduction has pointed out that the only information this study provides is that "pet mouse owners should not allow their mice to use electronic cigarettes.


According to The Independent, a new study has found that using e-cigarette fluids containing certain ingredients can cause heart rhythm irregularities, thereby increasing the risk of heart attacks.


A recent study published in Nature Communications suggests that e-cigarettes and their individual components can cause irregular heart rhythms and conduction defects in mice. The researchers conducted electrocardiogram tests on mice after acute inhalation of e-cigarette vapors. They argue that "our findings suggest that the chemical composition of e-cigarettes may increase cardiac risk by inducing changes that promote arrhythmogenesis and stimulate autonomic reflexes.


Experts in tobacco harm reduction and e-cigarettes quickly criticized the study. Professor Jacob George, Head of Cardiovascular Medicine and Therapeutics at the University of Dundee Medical School, said: "The metabolism of mice is very different from that of humans, and to be honest, any inference to long-term human health effects are at best speculative. If this were indeed true, given the large number of e-cigarette users worldwide, we would have expected to see a dramatic increase in cases of arrhythmia, which we have not seen in clinical practice.


The controversial nature of e-cigarettes brings into question the preliminary and speculative science surrounding its potential impact on human health, including the effects of nicotine on blood vessels. However, large-scale observational studies of users of nicotine replacement therapy have shown no increase in heart events. These findings should not deter those seeking to quit smoking from attempting e-cigarettes or nicotine replacement therapy. This early-stage preclinical research requires further clinical work before it can be considered directly related to human health.


Professor Peter Hajek, director of the Tobacco Dependence Research Department at Queen Mary University of London, added that "in this study, mice were exposed to aerosols from e-cigarette solvents with and without nicotine, as well as acrolein (a chemical that may be produced due to overheating) in e-cigarette liquid. Such exposure was associated with short-term changes in the mice's electrocardiograms and an increase in heart rate.


When talking about applying the results of this study to humans, there are several issues to consider. Electronic cigarette users are unlikely to be exposed to significant levels of acrolein since overheated e-liquid produces an unpleasant taste that people tend to avoid. While the study used exposure levels to other chemicals that humans can tolerate, the same dose may cause significant pain in much smaller mammals with more sensitive olfactory systems and varying tolerances to medication. It would be strange if animals exposed to aversive stimuli did not show a cardiovascular response. The reason for using mice in this study remains unclear. When experiments cannot be conducted on humans, animal models may be used, but comparing heart rate and electrocardiograms for electronic cigarette components and human smoking reactions is not without hurdles.


Professor Kevin McConway, Honorary Professor of Applied Statistics at The Open University in the UK, continues to criticize and has released a detailed statement saying: "As a statistician and not a biologist, I am unable to comment on the physiological details of this study. However, in my view, most aspects of the statistical analysis of the experimental results are reliable, and the study provides good evidence that certain components of e-cigarettes do indeed affect some aspects of mouse heart function when the mice are exposed to these components in the way done in this study. Nevertheless, while I believe that investigating the potential harmful effects of e-cigarette components is certainly worthwhile, and I also believe that animal experiments can play a role in this work, this work cannot answer some important questions.


I don't believe any knowledgeable commentator has suggested that using e-cigarettes is without risk. The important question is how the harm of using e-cigarettes compares to the harm that would result if the person did not use them. This, of course, depends on what the person would do if they did not use e-cigarettes. If they are a traditional smoker and e-cigarettes help them quit, then using e-cigarettes would prevent greater harm from their previous smoking habit. Other studies have shown that e-cigarettes can effectively help people quit smoking and are often more effective than nicotine replacement therapy like patches or gum. So, when used by smokers, the real question is not whether e-cigarettes are completely harmless, but whether they are safer than continuing to smoke or using other methods to quit, which may be less effective. This new study does not shed light on that question, and there is no evidence in its findings to suggest that using e-cigarettes is as harmful as smoking regular cigarettes, even in mice.


For those who are not yet smokers, electronic cigarette companies say it may be different. However, people still need to consider whether using electronic cigarettes may lead to other dangerous habits, such as using different drugs.


To the best of my understanding, this study has the potential to distinguish the effects of different components in e-cigarettes to some extent, which is an advantage. For example, this could lead to the development of safer e-cigarettes. However, as noted by the researchers, the reactions to various chemicals observed in mice may not necessarily apply to humans, even though this study specifically looks at several components of e-cigarettes and their potential effects on mice. Therefore, there is still a lot of work to be done and all relevant factors must be taken into consideration.


In addition, the study used a very small number of female mice - only four - and these mice did not come into contact with most of the substances involved. This means that, as the researchers have themselves acknowledged, some of the potential conclusions about gender differences are not based on evidence. Finally, these mice were (of course) completely unfamiliar with e-cigarettes, and the researchers note that the effects may be very different for individuals who have experience with e-cigarettes or tobacco use.


Dr. Adam Jacobs, Senior Director of Biostatistics at Premier Research, provided commentary on the study, stating "This study suggests that mice exposed to e-cigarette aerosol in a closed space for 90 minutes experience short-term changes in heart rhythm. While the long-term effects of these changes are not yet clear, it seems prudent for pet owners to avoid exposing their rodents to e-cigarettes. For humans, while e-cigarettes cannot be considered completely safe, there is a significant amount of evidence showing it to be much safer than smoking combustible cigarettes. Therefore, smokers who switch from traditional cigarettes to e-cigarettes will greatly reduce their health risks.


Statement:


The content of this article is compiled from third-party information and is only intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the translator's skills, the translated article may not fully express the same meaning as the original text. Please refer to the original text for accuracy.


2FIRSTS remains completely aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report|South Korean Lawmaker Queries China Tobacco Regulator Over Synthetic Nicotine as Export-Rule Gaps Emerge
Special Report|South Korean Lawmaker Queries China Tobacco Regulator Over Synthetic Nicotine as Export-Rule Gaps Emerge
A South Korean lawmaker has asked China’s tobacco regulator to clarify rules for e-cigarettes containing synthetic nicotine amid questions over product declarations and possible tax losses. The dispute exposes gaps between Chinese export requirements and destination-market rules, while underscoring the global impact of China’s licensing and traceability policies.
Jul.10
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%
How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%
Logista France says tobacco consumption outside France’s official tobacconist network has become a large and structural market phenomenon, but official and industry estimates differ sharply. France’s TAFE study estimates that 17.7% of tobacco consumption escaped domestic taxation in 2023, with most of that volume attributed to cross-border purchasing rather than street sales. Some industry studies use broader off-channel definitions and put the figure above 50%. Meanwhile, French Customs seized 547.94 tonnes of tobacco in 2025, up 12%, showing continued pressure from illicit trade.
Sep.04
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
China-based China Tobacco Hubei Industrial Co., Ltd. has filed a patent application covering an oral nicotine product and its preparation method. The patent proposes a soft candy-shaped oral nicotine product containing nicotine ingredients, gelling agents, sweeteners and alkaline pH regulators. Through formulation adjustments and homogeneous or dual-layer structures, the technology aims to achieve different nicotine release profiles. The filing reflects exploration of new oral nicotine product formats and controlled nicotine delivery approaches.
Aug.06
UK Vape Brands Face White-Packaging and Flavour-Name Curbs in Youth-Appeal Crackdown
UK Vape Brands Face White-Packaging and Flavour-Name Curbs in Youth-Appeal Crackdown
The UK government and devolved administrations have launched a 12-week consultation on proposals to make vapes less appealing to children, including plain white packaging, limits on device colours, restrictions on flavour names and changes to how products are displayed in shops.
Jul.10
IQOS Global Flagship Space to Open in Tokyo Ginza as PMI Expands Consumer Experience Strategy
IQOS Global Flagship Space to Open in Tokyo Ginza as PMI Expands Consumer Experience Strategy
Philip Morris Japan (PMJ) announced that it will open “IQOS Flagship Ginza” in Tokyo on September 4, 2026. The location will become the first global flagship space for PMI’s IQOS brand. PMJ said the venue will target adult smokers aged 20 and above and combine product experiences, community engagement and local cultural elements. The design will incorporate Japanese natural aesthetics and traditional craftsmanship. The launch reflects PMI’s broader strategy of strengthening consumer engagement through experiential retail and brand spaces. The existing IQOS Store Ginza is scheduled to close on August 30, 2026.
Jul.21